Prospective study evaluating performance of first-trimester combined screening for trisomy 21 using repeat sampling of maternal serum markers PAPP-A and free β-hCG

Ultrasound in Obstetrics and Gynecology

Volumn 40, Issue 3, 2012, Pages 276-281

  Ekelund, C ^a   Wright, D ^b   Ball, S ^b   Kirkegaard, I ^c   Norgaard P ^a   Sorensen S ^a   Friis Hansen, L ^d   Jorgensen F S ^a   Torring N ^c   Bech, B H ^e   Petersen, O B ^c   Tabor, A ^a  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d University of Copenhagen   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

combined first trimester screening; free beta hCG; maternal serum markers; nuchal translucency; PAPP A; screening for trisomy 21

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PAPPA1 PROTEIN, HUMAN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; BLOOD; DENMARK; DOWN SYNDROME; ECHOGRAPHY; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; METHODOLOGY; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL DIAGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DENMARK; DOWN SYNDROME; FEMALE; HUMANS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ULTRASONOGRAPHY, PRENATAL;

EID: 84865464888     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.12266     Document Type: Article

References (20)

1. Ekelund CK, Jørgensen FS, Petersen OB, Sundberg K, Tabor A,; Danish Fetal Medicine Research Group. Impact of a new national screening policy for Down's syndrome in Denmark: population based cohort study. BMJ 2008; 337: a2547.
2. Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH,. Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 2009; 34: 14-18.
3. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O,. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226.
4. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH,. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
5. Wright D, Spencer K, Kagan KK, Tørring N, Petersen OB, Christou A, Kallikas J, Nicolaides KH,. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation. Ultrasound Obstet Gynecol 2010; 36: 404-411.
6. Cuckle HS, van Lith JM,. Appropriate biochemical parameters in first-trimester screening for Down syndrome. Prenat Diagn 1999; 19: 505-512.
7. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K,. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002; 39: 567-576.
8. Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH,. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 2002; 20: 219-225.
9. Borrell A, Casals E, Fortuny A, Farre MT, Gonce A, Sanchez A, Soler A, Cararach V, Vanrell JA,. First-trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional study. Prenat Diagn 2004; 24: 541-545.
10. Kirkegaard I, Petersen OB, Uldbjerg N, Torring N,. Improved performance of first-trimester combined screening for trisomy 21 with the double test taken before a gestational age of 10 weeks. Prenat Diagn 2008; 28: 839-844.
11. Office for National Statistics. Birth Statistics. Review of the Registrar General on births and patterns of family building in England and Wales. Series FM1, No. 29-31. Stationery Office: London, 2002.
12. Screening for Down's syndrome: UK NSC Policy recommendations 2011-2014 Model of Best Practice (/http://fetalanomaly.screening.nhs.uk/ standardsandpolicies). 2011.
13. Palomaki GE, Steinort K, Knight GJ, Haddow JE,. Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. Obstet Gynecol 2006; 107: 367-375.
14. Wald NJ, Bestwick JP, Morris JK,. Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenat Diagn 2006; 26: 514-523.
15. Wright DE, Bradbury I,. Repeated measures screening for Down's Syndrome. BJOG 2005; 112: 80-83.
16. Spencer K, Cuckle HS,. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates? Prenat Diagn 2002; 22: 903-906.
17. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH,. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
18. Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH,. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006; 195: 109-114.
19. Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH,. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33: 18-22.
20. Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH,. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33: 512-517.